Sorry, you need to enable JavaScript to visit this website.

Study Investigating if Treatment with Rivipansel Shortened the Length of Hospital Stay For Patients with Sickle Cell Disease Vaso-Occlusive Crisis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Category & Conditions: Rare Diseases
Medicine: Rivipansel (GMI-1070)
ClinicalTrials.gov Identifier (NCT): NCT02187003
Protocol ID: B5201002
    Share
PrintDownload
Open Plain Language Summary Result: Click here